The Life Sciences team guided Cytospire Therapeutics ("Cytospire") on the closing of an oversubscribed $83 million Series A financing supported by a strong syndicate of new and existing biotech investors. Cytospire will use the proceeds to advance its pipeline of first-in-class pan-gamma delta T cell engagers, including its lead programme, CYT X300, which is currently being advanced through IND-enabling preclinical studies and GMP manufacturing. A first-in-human clinical study is being planned to evaluate CYT X300 as a treatment for EGFR-positive solid tumors, such as colorectal, head and neck and non-small cell lung cancers.
Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells. Its core technology allows binding and activation of both tissue/tumor and blood resident gamma delta T cells. This opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to CD3 T cell engagers due to toxicity. There are broad opportunities for Cytospire's gamma delta T cell engagers in solid and haematological malignancies, as well as in autoimmune disease.
The Goodwin team was led by Sophie McGrath, Maria Dragun, and Kerry Corrigan.
For more information on the deal, please read the press release.